ClinicalTrials.gg
CompletedNCT00533273CORD-IIUpdated Dec 2, 2017Results posted

Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

A Phase 3 interventional study of collagenase clostridium histolyticum in Advanced Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This 12-month study had two phases: a 90-day double-blind, randomized, placebo-controlled phase and a nine-month open-label extension phase. Before treatment, eligible subjects were stratified by the primary joint type (30 metacarpophalangeal [MP] joints and 30 proximal interphalangeal [PIP] joints) and by severity of the primary joint contracture (ie, up to 50° or >50° for MP joints and up to 40° or >40° for PIP joints) and then randomized in a 2:1 ratio to either AA4500 0.58 mg or placebo. Upon completion of the double-blind phase (ie, 90-day evaluation after the first injection), all subjects were eligible to enter the open-label extension phase of the study in which they were followed for an additional nine months. Subjects who required further treatment because they either did not achieve reduction in contracture to 5° or less, the cord affecting the primary joint received placebo, another cord received less than three injections of AA4500, or they had untreated cords that were affecting other joints had the option to receive up to five additional injections of AA4500 0.58 mg in the open-label extension phase, with individual cords receiving up to three injections of AA4500.

This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 [NCT00528606] and AUX-CC-859 [NCT00533273]) and 7 non-pivotal studies were evaluated.

02

Conditions studied

  • Advanced Dupuytren's Disease
03

In context

Lead sponsor

Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.

First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100°, for MP (80° for PIP) joints, caused by a palpable cord.
  • Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
  • Were naive to AA4500 treatment
  • Were judged to be in good health, based upon the results of a medical history, physical examination, and safety laboratory profile.

Exclusion criteria

Exclusion Criteria:

  • Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
  • Had received a treatment for advanced Dupuytren's disease, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug.
  • Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    AA4500 0.58 mg

    Biological: collagenase clostridium histolyticum

  • Placebo comparator
    Placebo

    Biological: collagenase clostridium histolyticum

Interventions

  • Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.

    Also known as: XIAFLEX®, AA4500

06

What researchers measure

Primary outcomes

  1. Reduction in Primary Joint Contracture to 5° or Less

    Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

    Time frame: Within 30 days after last injection

Secondary outcomes

  1. Clinical Improvement in Primary Joint After the Last Injection

    Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

    Time frame: Baseline, Within 30 days after last injection

  2. Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection

    Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture

    Time frame: Baseline, Day 30 after last injection

  3. Change From Baseline Range of Motion in Primary Joint After the Last Injection

    Change in degree of range of motion in primary joint measured as last available post-injection range of motion - baseline range of motion

    Time frame: Baseline, Day 30 after last injection

  4. Time to Reach Clinical Success in Primary Joint

    Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories

    Time frame: Within 30 days after last injection

  5. Clinical Success in Primary Joint After the First Injection

    Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

    Time frame: Within 30 days after first injection

  6. Clinical Improvement in Primary Joint After the First Injection

    Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

    Time frame: Baseline, Within 30 days after first injection

  7. Percent Reduction From Baseline Contracture of Primary Joint After the First Injection

    Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture

    Time frame: Baseline, Day 30 after first injection

  8. Change From Baseline Range of Motion in Primary Joint After the First Injection

    Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion

    Time frame: Baseline, Day 30 after first injection

  9. Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection

    Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

    Time frame: Within 30 days after last injection

  10. Clinical Improvement in Non-Primary Joint After the Last Injection

    Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

    Time frame: Baseline, Within 30 days after last injection

  11. Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection

    Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture

    Time frame: Baseline, Day 30 after last injection

  12. Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection

    Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion - baseline range of motion

    Time frame: Baseline, Day 30 after last injection

  13. Time to Reach Clinical Success in Non-Primary Joint

    Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories

    Time frame: Within 30 days after last injection

  14. Clinical Success in Non-Primary Joint After the First Injection

    Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

    Time frame: Within 30 days after first injection

  15. Clinical Improvement in Non-Primary Joint After the First Injection

    Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

    Time frame: Baseline, Within 30 days after first injection

  16. Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection

    Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture

    Time frame: Baseline, Day 30 after first injection

  17. Change From Baseline Range of Motion in Non-Primary Joint After the First Injection

    Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion

    Time frame: Baseline, Day 30 after first injection

07

Results

Posted Oct 22, 2010

Participant flow

Double-blind
Participant flow — Double-blind
MilestoneAA4500 0.58 mgPlacebo
Started4521
Completed4519
Not completed02
Withdrew: Withdrew consent02
Open-label
Participant flow — Open-label
MilestoneAA4500 0.58 mgPlacebo
Started640
Completed580
Not completed60
Withdrew: Withdrawal by subject60

Outcome measures

PrimaryReduction in Primary Joint Contracture to 5° or Less

Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

Time frame:
Within 30 days after last injection
Reported as:
Number · Percentage of Joints
Reduction in Primary Joint Contracture to 5° or Less
Percentage of JointsAA4500 0.58 mgPlacebo
Reduction in Primary Joint Contracture to 5° or Less44.44.8
Statistical analysis
  • AA4500 0.58 mg vs Placebo · Cochran-Mantel-Haenszel · p = <.001
SecondaryClinical Improvement in Primary Joint After the Last Injection

Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

Time frame:
Baseline, Within 30 days after last injection
Reported as:
Number · Percentage of Joints
Clinical Improvement in Primary Joint After the Last Injection
Percentage of JointsAA4500 0.58 mgPlacebo
Clinical Improvement in Primary Joint After the Last Injection77.814.3
Statistical analysis
  • AA4500 0.58 mg vs Placebo · Cochran-Mantel-Haenszel · p = <.001
SecondaryPercent Reduction From Baseline Contracture of Primary Joint After the Last Injection

Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture

Time frame:
Baseline, Day 30 after last injection
Reported as:
Mean · Percentage of change
Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection
Percentage of changeAA4500 0.58 mgPlacebo
Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection70.5 ± 29.2113.6 ± 26.10
Statistical analysis
  • AA4500 0.58 mg vs Placebo · ANOVA · p = <.001
SecondaryChange From Baseline Range of Motion in Primary Joint After the Last Injection

Change in degree of range of motion in primary joint measured as last available post-injection range of motion - baseline range of motion

Time frame:
Baseline, Day 30 after last injection
Reported as:
Mean · Degrees
Change From Baseline Range of Motion in Primary Joint After the Last Injection
DegreesAA4500 0.58 mgPlacebo
Change From Baseline Range of Motion in Primary Joint After the Last Injection35.4 ± 17.777.6 ± 14.88
Statistical analysis
  • AA4500 0.58 mg vs Placebo · ANOVA · p = <.001
SecondaryTime to Reach Clinical Success in Primary Joint

Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories

Time frame:
Within 30 days after last injection
Reported as:
Number · Percentage of Joints
Time to Reach Clinical Success in Primary Joint
Percentage of JointsAA4500 0.58 mgPlacebo
Injection 1, Day 12.20.0
Injection 1, Day 76.74.8
Injection 1, Day 3017.80.0
Injection 2, Day 10.00.0
Injection 2, Day 74.40.0
Injection 2, Day 308.90.0
Injection 3, Day 14.40.0
Injection 3, Day 70.00.0
Injection 3, Day 300.00.0
Did not reach Clinical Success55.695.2
SecondaryClinical Success in Primary Joint After the First Injection

Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

Time frame:
Within 30 days after first injection
Reported as:
Number · Percentage of Joints
Clinical Success in Primary Joint After the First Injection
Percentage of JointsAA4500 0.58 mgPlacebo
Clinical Success in Primary Joint After the First Injection26.74.8
Statistical analysis
  • AA4500 0.58 mg · Cochran-Mantel-Haenszel · p = .014
SecondaryClinical Improvement in Primary Joint After the First Injection

Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

Time frame:
Baseline, Within 30 days after first injection
Reported as:
Number · Percentage of Joints
Clinical Improvement in Primary Joint After the First Injection
Percentage of JointsAA4500 0.58 mgPlacebo
Clinical Improvement in Primary Joint After the First Injection60.04.8
Statistical analysis
  • AA4500 0.58 mg vs Placebo · Cochran-Mantel-Haenszel · p = <.0001
SecondaryPercent Reduction From Baseline Contracture of Primary Joint After the First Injection

Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture

Time frame:
Baseline, Day 30 after first injection
Reported as:
Mean · Percentage of change
Percent Reduction From Baseline Contracture of Primary Joint After the First Injection
Percentage of changeAA4500 0.58 mgPlacebo
Percent Reduction From Baseline Contracture of Primary Joint After the First Injection58.5 ± 31.746.0 ± 20.79
Statistical analysis
  • AA4500 0.58 mg vs Placebo · ANOVA · p = <.001
SecondaryChange From Baseline Range of Motion in Primary Joint After the First Injection

Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion

Time frame:
Baseline, Day 30 after first injection
Reported as:
Mean · Degrees
Change From Baseline Range of Motion in Primary Joint After the First Injection
DegreesAA4500 0.58 mgPlacebo
Change From Baseline Range of Motion in Primary Joint After the First Injection28.6 ± 17.413.6 ± 9.51
Statistical analysis
  • AA4500 0.58 mg vs Placebo · ANOVA · p = <.001
SecondaryReduction in Non-primary Joint Contracture to 5° or Less After the Last Injection

Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

Time frame:
Within 30 days after last injection
Reported as:
Number · Percentage of Joints
Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection
Percentage of JointsAA4500 0.58 mg
Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection53.9
SecondaryClinical Improvement in Non-Primary Joint After the Last Injection

Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

Time frame:
Baseline, Within 30 days after last injection
Reported as:
Number · Percentage of Joints
Clinical Improvement in Non-Primary Joint After the Last Injection
Percentage of JointsAA4500 0.58 mg
Clinical Improvement in Non-Primary Joint After the Last Injection70.8
SecondaryPercent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection

Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture

Time frame:
Baseline, Day 30 after last injection
Reported as:
Mean · Percentage of change
Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection
Percentage of changeAA4500 0.58 mg
Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection66.4 ± 34.63
SecondaryChange From Baseline Range of Motion in Non-Primary Joint After the Last Injection

Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion - baseline range of motion

Time frame:
Baseline, Day 30 after last injection
Reported as:
Mean · Degrees
Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection
DegreesAA4500 0.58 mg
Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection25.2 ± 16.80
SecondaryTime to Reach Clinical Success in Non-Primary Joint

Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories

Time frame:
Within 30 days after last injection
Reported as:
Number · Percentage of Joints
Time to Reach Clinical Success in Non-Primary Joint
Percentage of JointsAA4500 0.58 mg
Injection 1, Day 16.7
Injection 1, Day 718.0
Injection 1, Day 3011.2
Injection 2, Day 00.0
Injection 2, Day 19.0
Injection 2, Day 72.2
Injection 2, Day 304.5
Injection 3, Day 00.0
Injection 3, Day 10.0
Injection 3, Day 70.0
Injection 3, Day 302.2
Did not reach Clinical Success46.1
SecondaryClinical Success in Non-Primary Joint After the First Injection

Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

Time frame:
Within 30 days after first injection
Reported as:
Number · Percentage of Joints
Clinical Success in Non-Primary Joint After the First Injection
Percentage of JointsAA4500 0.58 mg
Clinical Success in Non-Primary Joint After the First Injection36.0
SecondaryClinical Improvement in Non-Primary Joint After the First Injection

Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

Time frame:
Baseline, Within 30 days after first injection
Reported as:
Number · Percentage of Joints
Clinical Improvement in Non-Primary Joint After the First Injection
Percentage of JointsAA4500 0.58 mg
Clinical Improvement in Non-Primary Joint After the First Injection58.4
SecondaryPercent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection

Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture

Time frame:
Baseline, Day 30 after first injection
Reported as:
Mean · Percentage of change
Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection
Percentage of changeAA4500 0.58 mg
Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection54.7 ± 38.37
SecondaryChange From Baseline Range of Motion in Non-Primary Joint After the First Injection

Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion

Time frame:
Baseline, Day 30 after first injection
Reported as:
Mean · Degrees
Change From Baseline Range of Motion in Non-Primary Joint After the First Injection
DegreesAA4500 0.58 mg
Change From Baseline Range of Motion in Non-Primary Joint After the First Injection20.5 ± 17.52

Adverse events

Collected over Non-serious adverse events (non-SAEs) were collected from time of study drug administration, serious adverse events (SAEs) were collected from time subject signed ICF. Non-SAEs & SAEs were collected until 30 days after completion or discharge from study.. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500 0.58 mg—7/63 (11.1%)63/63 (100%)
Placebo—1/21 (4.8%)10/21 (47.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAA4500 0.58 mgPlacebo
Inguinal hernia repairSocial circumstances0/631/21
Abdominal hernia repairSurgical and medical procedures1/630/21
Atrial fibrillationCardiac disorders1/630/21
CholecystitisHepatobiliary disorders1/630/21
Dupuytren's contractureMusculoskeletal and connective tissue disorders1/630/21
Dupuytren's contracture operationSurgical and medical procedures1/630/21
Ligament injuryInjury, poisoning and procedural complications1/630/21
Orbital cystEye disorders1/630/21
PneumoniaInfections and infestations1/630/21
Sensory disturbanceNervous system disorders1/630/21
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAA4500 0.58 mgPlacebo
Oedema peripheralGeneral disorders54/632/21
ContusionInjury, poisoning and procedural complications46/632/21
Pain in extremityMusculoskeletal and connective tissue disorders36/633/21
Injection site painGeneral disorders28/632/21
Injection site haemorrhageGeneral disorders27/630/21
Injection site swellingGeneral disorders23/633/21
TendernessGeneral disorders20/630/21
LymphadenopathyBlood and lymphatic system disorders13/630/21
PruritusSkin and subcutaneous tissue disorders13/630/21
Axillary painMusculoskeletal and connective tissue disorders8/630/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500 0.58 mgPlaceboTotal
<=18 years000
Between 18 and 65 years25934
>=65 years201232
Age, Continuous
Age, Continuous(years)AA4500 0.58 mgPlaceboTotal
Mean63.0 ± 7.865.5 ± 11.163.8 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)AA4500 0.58 mgPlaceboTotal
Female6410
Male391756
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AA4500 0.58 mgPlaceboTotal
White452166
Region of Enrollment
Region of Enrollment(participants)AA4500 0.58 mgPlaceboTotal
Australia452166
08

Study locations

7 sites
  • Rivercity Research
    Auchenflower, Queensland 4067, Australia
  • Brisbane Hand & Upper Limb Clinic
    Brisbane, Queensland 4000, Australia
  • Caboolture Clinical Research Centre
    Caboolture, Queensland 4510, Australia
  • Peninsula Clinical Research Centre
    Kippa Ring, Queensland 4019, Australia
  • Menzies Reserarch Institute
    Hobart, Tasmania 7000, Australia
  • Emeritus Research
    Malvern, Victoria 3144, Australia
  • Royal Perth Hospital
    Shenton Park, Western Australia 6007, Australia
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2007 to primary completion in Sep 2008, 13 months.

Results were first posted in Oct 2010, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2007
First posted
Sep 21, 2007
StartActual
Aug 2007
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Oct 22, 2010
Last update
Dec 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00533273
Responsible party
Sponsor
First posted
Sep 21, 2007
Start date
Aug 2007
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Oct 22, 2010
Last update
Dec 2, 2017

Study contacts

Veronica Urdaneta, MD
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion